AAO News Archive
- Deal struck to develop integrin antagonist treatment
- New low-add multifocal IOLs yield higher patient satisfaction
- Regeneron, Bayer to develop AMD combination therapy
- FDA approves wide-field imaging system for newborns
- Brain mapping may someday lead to vision-restoring therapies
- FDA warns of loose safety seals on eye drops
- Stem cells regrow human lens, corneal tissue
Find an Eye MD near you!
- Details
Scientists have shown that human cells can be reprogrammed to grow sheets of corneal tissue, and that stem cells in the human eye can be coaxed to regrow clear lenses after cataract surgery.
- Details
Acucela Inc. and YouHealth Eyetech Inc. have signed an agreement to develop a pharmacologic treatment for cataracts.
- Details
Two late-stage trials identify safety issues for Aerie Pharmaceuticals new glaucoma treatment, Rhopressa.
Read more: New safety concerns for Aerie’s experimental glaucoma treatment
- Details
Formycon is solidifying its position in ophthalmologic follow-on products with the development of a biosimilar for aflibercept. It joins the follow-on version of ranibizumab that is already in Phase 3 clinical trials.
Read more: Biosimilars for aflibercept and ranibizumab in development
- Details
Using a new low-vision assessment tool developed specifically for patients implanted with retinal prostheses, investigators showed that Second Sight's Argus II improves the ability of blind individuals to perform everyday tasks.
Read more: New data show Argus II helps the blind perform daily tasks
- Details
The Triggerfish contact lens has a built-in sensor that could help identify patients at higher risk of glaucoma progression.
Read more: FDA approves smart contact lens for 24-hour IOP monitoring